SANOFI-AVENTIS (EPA:SAN) ESMO late-breaking data show Libtayo® (cemiplimab) and chemotherapy first-line treatment combination significantly improved overall survival in patients with advanced NSCLC
Directive transparence : information réglementée
19/09/2021 17:30
01/06/2023 07:30
01/06/2023 07:30
21/05/2023 20:17
21/05/2023 20:17
17/05/2023 22:01
17/05/2023 22:01
12/05/2023 10:50
04/05/2023 08:00
04/05/2023 08:00
27/04/2023 14:40